The Cooper Companies, Inc.
HealthcareNASDAQ:COO · NASDAQ Global Select
+$0.37 today
Vol 1.89M · Avg 2.54M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
4.6%
avg 10.4%
ROIC
4.0%
avg 5.4%
ROA
3.0%
avg 6.8%
Analysis
ROE is currently the strongest return metric at 4.6% versus its period average of 10.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Albert G. White | President, Chief Executive Officer & Non-Independent Director | $2.71M | — | 56 | $254,491.00 | 0.13% |
Daniel G. McBride | Executive VP, COO General Counsel & Secretary | $1.45M | — | 62 | $76,007.00 | 0.04% |
Brian G. Andrews | Executive VP, CFO, Treasurer & Principal Accounting Officer | $1.31M | — | 47 | $10,430.00 | <0.01% |
Holly R. Sheffield | President of CooperSurgical, Inc. | $1.12M | — | 55 | $1,592.00 | <0.01% |
Gerard H. Warner | President of CooperVision, Inc. | $1.09M | — | 61 | $29,837.00 | 0.02% |
Agostino Ricupati | Senior Vice President & Tax | $670,709.00 | — | 59 | $0.00 | <0.01% |
Kim Duncan | Vice President of Investor Relations & Risk Management | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
10
$2.52M
Sells
0
$0.00
Net Sentiment
+$2.52M
Net buying
Most Active
Kurzius Lawrence Erik
2 transactions
Analysis
Insiders reported 10 buys worth $2.52M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $2.52M. Kurzius Lawrence Erik was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -6.4% | +2.6% (14yr)6 analysts |
| Revenue | N/A | N/A | +7.5% | +7.6% (14yr)5 analysts |
| Net Income | N/A | N/A | -6.4% | +13.4% (14yr)5 analysts |
| EBIT | N/A | N/A | -5.8% | +9.2% (14yr)5 analysts |
Analysis
Recent growth has been strongest in Revenue at +7.5% over three years. Forward estimates point to Net Income at +13.4% (14yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Hologic, Inc.
HOLX
$16.97B
Neurocrine Biosciences, Inc.
NASDAQ:NBIX
$16.06B
Solventum Corporation
NYSE:SOLV
$13.66B
Smith & Nephew plc
NYSE:SNN
$12.97B
Fresenius Medical Care AG & Co. KGaA
NYSE:FMS
$12.36B
ICON Public Limited Company
NASDAQ:ICLR
$11.19B
Summit Therapeutics Inc.
NASDAQ:SMMT
$10.86B
Universal Health Services, Inc.
NYSE:UHS
$9.17B
Tempus AI, Inc.
NASDAQ:TEM
$8.35B
Doximity, Inc.
NYSE:DOCS
$3.75B
Who manages COO?
The Cooper Companies, Inc. (COO) lists 7 active executives. The top listed executive is Daniel G. McBride, Executive VP, COO General Counsel & Secretary.
Are COO insiders buying or selling?
Recent insider activity shows net buying of $23.48M.
Explore More
Continue the stock analysis
Jump to another research area for this company.